Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology or original data
PubMed 35408810 · doi:10.3390/ijms23073451
What was done
This narrative review synthesized literature on the pharmacological characteristics, clinical outcomes, and genetic determinants (including variations in the GLP-1 receptor and intracellular signaling pathways) that influence therapeutic response and non-responsiveness to GLP-1 receptor agonists in type 2 diabetes mellitus and obesity.
What was found
The abstract provides no quantitative data or specific numerical results. It describes established physiological mechanisms of GLP-1 receptor agonists, notes the efficacy of higher-dose semaglutide for weight loss, and attributes non-response in certain patients to multifactorial disease etiology and genetic variability in receptor and signaling pathways.
Why it matters
Understanding the pharmacogenetic and clinical determinants of GLP-1 receptor agonist non-responsiveness helps frame future precision-medicine approaches for patients with type 2 diabetes and obesity who fail to achieve expected glycemic or weight reduction targets.
Limits
As a narrative review, it presents no original primary data, systematic search criteria, or pooled meta-analytic effect sizes. The abstract does not identify specific genetic variants or quantify non-responder prevalence.
Cited by
- supports At low antidiabetic doses, GLP-1 receptor activators act by inhibiting pancreatic alpha cells and suppressing glucagon secretion.